Prof. Dr. Tanja de Gruijl to Present Clinical Data on ORCA-010 at ESMO Immuno-Oncology Congress 2024

Amsterdam, Netherlands – November 2024

ORCA Therapeutics B.V., a Dutch biopharmaceutical company pioneering innovative oncolytic immunotherapies for cancer treatment, today announced that Professor Dr. Tanja de Gruijl will present clinical data from the company’s lead product ORCA-010 at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress in Geneva, Switzerland.

The presentation, titled “ORCA-010 Oncolytic Therapy: Inducing Tumor-Specific Immune Responses and Activation of Tumor Microenvironment in Treatment-Naïve Prostate Cancer,” will highlight key immunological findings from ORCA’s Phase I/IIA clinical trial. Patients treated with ORCA-010 presented with immune infiltration highly associated with regions containing cancer cells, activation of the tumor microenvironment and the induction of systemic tumor-specific immune responses.

About Professor Dr. Tanja de Gruijl

Professor de Gruijl is a distinguished leader in tumor immunology, holding the position of Professor of Translational TumourImmunology and the Fenna Diemer Lindeboom Chair at Amsterdam University Medical Centers. With over 25 years of experience and more than 250 publications, her expertise spans from preclinical research to immune monitoring in clinical trials. Her groundbreaking work includes research on tumor-draining lymph nodes, immunological enhancement of oncolytic adenoviruses, and targeted immune cell therapies. Prof. de Gruijlserves on the board of directors of the Society for the Immunotherapy of Cancer (SITC) and is an associate editor for several prestigious journals in the field.

About ORCA-010

ORCA-010 is a state-of-the-art oncolytic adenovirus therapy designed to specifically kill tumor cells, modify the tumor microenvironment while inducing systemic anti-tumor immune responses. The Phase I/IIA trial focuses on treatment-naïve, early-stage prostate cancer patients. Analyses suggest not only the potential to induce stabilization or decrease of PSA, but also impact on distant tumors, long-term immunological activation of the tumor microenvironment and induction of a systemic anti-tumor immune response.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com